Equisulin M 50 Injection is a combination insulin preparation containing 50% Insulin Isophane and 50% Human Insulin, formulated for the management of diabetes mellitus requiring insulin therapy. This biphasic insulin suspension provides both intermediate and short-acting insulin components, enabling effective glycemic control by addressing both basal and prandial insulin requirements. The Insulin Isophane component ensures a prolonged duration of action, facilitating sustained insulin levels to control fasting blood glucose, while the Human Insulin component offers rapid onset to manage postprandial glucose excursions. Equisulin M 50 Injection is indicated for patients with type 1 and type 2 diabetes mellitus when diet, exercise, and oral hypoglycemic agents alone do not achieve adequate glycemic control. The injection should be administered subcutaneously, with dosage and timing individualized based on patient’s metabolic needs, blood glucose monitoring, and lifestyle factors. Careful dose titration is essential to minimize the risk of hypoglycemia. This product should be stored under recommended conditions to maintain potency. Patients should be educated on proper injection technique, storage, and recognition of hypoglycemia symptoms. Equisulin M 50 Injection is a vital therapeutic option in comprehensive diabetes management to optimize glycemic control and reduce the risk of diabetes-related complications.